We use cookies for behaviour analytics. Learn more
Healthcare · Equity Analysis
Merck & Co. Inc. (MRK) Stock Analysis - DCF Valuation & AI Disruption Risk
By Anton Ladnyi, CFA · ex-Goldman Sachs · ex-J.P. MorganPublished Updated
MRK — Q2 2026 (reported Aug 4) beat on both lines: revenue $16.61B (+5% YoY, beat $16.36B est.) with Keytruda up 5% to $8.37B (including $463M from the new subcutaneous QLEX formulation, itself beating estimates); but GAAP EPS was a loss of $0.13 including a $2.31/share charge tied to the newly-closed $6.7B Terns Pharmaceuticals acquisition, and full-year adjusted EPS guidance was cut sharply to $2.66-2.76 (from $5.04-5.16) purely on Terns/Cidara deal charges even as full-year revenue guidance was nudged up to $66.3-67.3B.
Quantitative model rating — not individualized investment advice.
How Is This Rating Calculated?
A.L. Capital Advisory Equity Composite model · calculated 2026-08-08. Four calculation steps, in order — steps 1, 2 and 4 are rules-based; step 3 is a disclosed qualitative analyst overlay mapped to a fixed numerical scale:
1. Margin of safety → quantitative grade
MRK's margin of safety is +25.16% (base case $172 vs. price $128.58). Margin of safety here is defined as (fair value − price) / fair value — this is the formula the quant grade below is actually assigned from. It is not the same figure as the gauge's "Upside to Base" pill above, which uses (fair value − price) / price and will read a larger number for the same inputs. For comparison, the pure (unblended) DCF output alone implies a margin of safety of +53.63% (pure DCF base $277 vs. price $128.58) — the gap between this and the +25.16% blended figure above reflects the analyst-consensus blend.
Blended valuation margin-of-safety bands
Margin of safety
Quant grade
Score
MOS > 20.00%
Strong Buy
5.0
10.00% < MOS ≤ 20.00%
Buy
4.0
−10.00% < MOS ≤ 10.00%
Hold
3.0
−20.00% < MOS ≤ −10.00%
Reduce
2.0
MOS ≤ −20.00%
Avoid
1.0
2. Auto fundamental penalty
No fundamental red flags triggered · total: +0.0
Automatic fundamental-penalty rules
Rule
Threshold
Penalty
P/E extreme
Forward (or trailing) P/E > 80x
−1.0
P/E elevated
Forward (or trailing) P/E 50–80x
−0.5
Earnings deterioration, significant
Earnings growth < −20%
−1.0
Earnings deterioration, mild
Earnings growth −5% to −20%
−0.5
Stagnant top-line
Revenue growth < 3%
−0.5
Unsustainable dividend
Payout ratio > 120%
−0.5
Rules are cumulative (multiple can fire on the same ticker) and purely mechanical — no analyst judgment is involved in step 2.
3. Thesis conviction modifier
Analyst conviction: medium-high · modifier: +0.00. This is a qualitative analyst judgment on the written thesis, mapped to a fixed numeric modifier below — it is not algorithmically derived from a measurable indicator.
Analyst-conviction modifier scale
Conviction level
Modifier
Very High
+1.00
High
+0.60
Medium
+0.00
Low
-0.60
Very Low
-1.00
General guidance for the assigning analyst (not an algorithmic rule — conviction is assigned by editorial judgment on the written thesis, not computed): Very High/High — multiple thesis pillars confirmed by the most recent reported quarter, no unresolved red flags. Medium — mixed evidence, or a thesis not yet differentiated enough to lean either direction. Low/Very Low — one or more thesis pillars deteriorating, or a material data-quality concern. Assigned and reviewed each time the underlying thesis is updated (see the thesis "last updated" date on this page).
This is the exact formula the model runs — not a post-hoc explanation. Source: composite_grade.py, A.L. Capital Advisory Equity Composite.
MRK Price Target & Rating
MRK's quantitative grade is Strong Buy, with limited downside risk (CVaR -8.3%), and quality metrics (net margin 5%). Merck & Co. Inc. (MRK) trades at $128.58 with a Strong Buy composite rating: a trailing P/E of 102.9x at a 368% premium to sector median, net margins of 4.8%, a blended fair-value range of $128–$214 suggesting a +25% margin of safety, beta 0.21 (defensive risk profile).
What Is MRK's DCF Intrinsic Value and Blended Fair Value Range?
MRK's blended fair-value range is $128–$214 (base case $172), against a current price of $128.58.
MRK blended fair-value gauge — bear case $128, base case $172, bull case $214, current price $128.58.
Price & DCF data as of
How Does MRK's Margin of Safety Change as the Price Moves?
Drag to simulate MRK's price moving between the blended bear ($128) and bull ($214) fair-value anchors — left for a price fall, right for a rise — and see how the margin of safety vs A.L. Capital Advisory's $172 blended base-case fair value changes. Starting point: the page's as-of price of $128.58 on 2026-08-08.
DCF Assumptions
Two-stage earnings-based DCF on forward EPS of $9.60 (Yahoo Finance forwardEps: provider-aggregated next-fiscal-year consensus estimate, not a fixed trailing-12-month window): explicit 5-year forecast at the stage-1 growth rate below, discounted at the CAPM cost of equity, plus a Gordon Growth terminal value at the terminal growth rate, also discounted at the CAPM cost of equity. This model discounts projected EPS — an equity-level metric — directly, not free cash flow, so the cost of equity is the theoretically correct discount rate; this is not a debt-weighted WACC (no cost of debt or capital-structure weighting is applied). Source: A.L. Capital Advisory DCF engine (api.py).
DCF assumptions by scenario
Input
Bear
Base
Bull
Stage-1 (near-term) growth
4.50%
10.00%
15.00%
Terminal growth
2.50%
2.50%
2.50%
CAPM cost of equity (discount rate)
8.00%
7.41%
6.82%
Forecast horizon
5 years
5 years
5 years
CAPM cost of equity = risk-free rate (4.66%, a live 10-year Treasury yield (Yahoo Finance ^TNX) fetched at page-generation time, 2026-08-08T12:43:46+00:00 UTC) + beta (0.50) × 5.5% equity risk premium, floored at 6% and capped at 18%. Stage-1 growth is a sector-level base rate (bear/bull apply 0.45x/1.50x multipliers); terminal growth is held constant across scenarios. Bear/bull cost of equity applies a ±8% relative adjustment to the base rate, clamped to the same 6–18% band.
The DCF output above is not the final intrinsic value shown elsewhere on this page. It is blended with the Wall Street analyst consensus price target to avoid extreme single-model divergence, weighted by analyst coverage depth (26 analysts covering this stock → 25.00% DCF / 75.00% consensus). The blended figure is the intrinsic value used for margin-of-safety and the composite rating.
DCF-to-intrinsic-value blend by scenario
Scenario
Pure DCF value
Analyst target used
Blended intrinsic value (displayed)
Bear
$195.11
$105.00
$127.53
Base
$277.27
$136.65
$171.81
Bull
$389.78
$155.00
$213.69
Blended value = (25.00% × pure DCF) + (75.00% × analyst target). Bear/bull scenarios blend against the analyst low/high target rather than the mean.
Analyst-coverage-to-consensus-weight tiers
Analyst coverage
Weight
0–1 analysts
0.00% consensus / 100.00% DCF
2–4 analysts
40.00% consensus / 60.00% DCF
5–19 analysts
65.00% consensus / 35.00% DCF
20+ analysts
75.00% consensus / 25.00% DCF
The consensus weight is a fixed step function of analyst coverage depth (above), not adjusted for target age, dispersion, or outliers — the mean/low/high analyst targets are used as reported by the data provider with no filtering.
Key Takeaways
Valuation: Strong Buy grade — P/E 102.9x — blended fair-value range $128–$214 implies +25% margin of safety
Risk: CVaR -8.3% (95th percentile, 1-month) indicates moderate tail exposure; beta of 0.21 amplifies broad market moves in both directions
Strengths: Size 4.5/5, 5% net margin dominate the factor profile
Catalyst: Q3 2026 earnings (expected early November 2026) — first quarter absorbing the Terns/Cidara deal charges into run-rate adjusted EPS; Keytruda + Padcev PDUFA decision for cisplatin-eligible MIBC (Aug 17, 2026); continued QLEX subcutaneous Keytruda rollout metrics
Bear catalyst: Adjusted EPS guidance is cut again on operational (not one-time M&A) grounds; Keytruda growth decelerates below 3% YoY; the Aug 17 Padcev/MIBC PDUFA decision is a rejection or delay
Main riskP/E of 102.9x creates asymmetric downside on any earnings disappointment
Tail riskCVaR -8.3% over one month at the 95th percentile
Blended fair-value range$128–$214 blended fair-value range; margin of safety +25%
Best useCore large-cap Healthcare holding — not a source of diversified sector exposure
Next watchEarnings delivery consistency and margin trajectory
How Does MRK Score on the Five-Factor Quantitative Model?
MRK's composite five-factor score is 3.5/5, led by Volatility (5.0/5) and weakest on Value (2.0/5).
MRK five-factor radar — Value 2.0, Quality 3.0, Momentum 3.0, Volatility 5.0, Size 4.5 (out of 5).
Value
2.0 / 5
Quality
3.0 / 5
Momentum
3.0 / 5
Volatility
5.0 / 5
Size
4.5 / 5
MRK Five-Factor Quantitative Scores
Factor
Score
Value
2.0 / 5
Quality
3.0 / 5
Momentum
3.0 / 5
Volatility
5.0 / 5
Size
4.5 / 5
What Is MRK's AI-Era Durability and Disruption Risk?
AI Disruption Risk: Elevated
Merck's durability picture is a single-product concentration story: Keytruda generated $29.5 billion in 2024 revenue, roughly 40% of pharmaceutical sales, and loses U.S. exclusivity in late 2028 in what the industry frames as the largest single revenue-replacement challenge in modern pharma. Merck's defense combines lifecycle management -- the Keytruda QLEX subcutaneous reformulation targeting 30-40% patient conversion by 2028 to blunt biosimilar erosion -- with acquisitions (Prometheus for $10.8 billion in 2023, plus Verona Pharma and Cidara Therapeutics) meant to diversify into cardio-respiratory, immunology, and infectious-disease franchises; management now projects over $70 billion in non-risk-adjusted pipeline commercial opportunity by the mid-2030s. Near term, Gardasil sales fell 39% to about $5.2 billion in 2025 on China demand weakness and inventory overhang, an added drag layered on top of the looming Keytruda cliff. AI is not a meaningful driver of Merck's 2026 investment case. Watch trigger: adoption of Keytruda QLEX and whether Winrevair, Ohtuvayre, and tulisokibart show franchise-level revenue traction ahead of 2028.
Key Metrics
MRK Key Metrics — Merck & Co. Inc. 2026
Metric
Value
Current Price
$128.58
P/E Ratio (TTM)
102.9x
Forward P/E
13.4x
P/S Ratio
4.8
EV/EBITDA
23.8
Beta
0.21
Net Margin
4.8%
Debt/Equity
106.9%
Dividend Yield
2.64%
CVaR (95%, 1M)
-8.3%
Market Cap
$317.6B
1-Month CVaR Methodology
The 1M CVaR-95 figure shown in Key Metrics, the peer comparison table and this page's hero card is computed as follows:
Lookback: most recent 1 year of daily prices.
Return input: daily log returns on dividend/split-adjusted close prices.
Confidence level: 95% (worst 5% of the resulting rolling-month observations).
Quantile convention: floor-based cutoff — the worst floor(N × 0.05) rolling-month observations (minimum 1), not a rounded or interpolated percentile.
CVaR: arithmetic mean of that worst-5% tail, expressed as a percentage.
Corporate actions: reflected via adjusted-close pricing (dividends and splits are accounted for).
1M CVaR-95 by lookback window
Method
1M CVaR-95
Trailing 1-year historical
-8.3%
Trailing 3-year historical
-14.5%
Trailing 5-year historical
-13.7%
The 1-year figure is what appears elsewhere on this page. Because it is built from overlapping 21-day windows over a single year, it reflects roughly the last ~11 non-independent tail events and is sensitive to the specific market regime of that year — treat it as a trailing-window historical estimate, not a structurally stable long-run risk parameter. The 3- and 5-year figures use the same methodology over longer, more regime-diverse histories.
This is a separate calculation from the 1-Day VaR/CVaR shown in the Tail Risk Profile chart below, which uses raw (non-overlapping) daily returns rather than rolling monthly sums — see that chart's own methodology note for the daily-horizon convention.
Tail Risk Profile
Historical Simulation · Daily Log Returns
MRK — Daily Return Distribution
Merck & Co. Inc. · 250 trading days · CVaR illustrated on real data
Aug 2025 – Aug 2026
Daily log returns
95%
-2.46%
1-Day VaR · 95%
95th-percentile loss threshold
-3.05%
1-Day CVaR · 95%
Avg loss in tail
13
Days in tail
of 250 sessions
250
Daily returns
Aug 2025 – Aug 2026
Historical VaR uses the nearest-rank convention: the worst observation within the tail (empirical (1−confidence) fraction of trading days). Historical CVaR is the arithmetic mean of all observations at or below that VaR threshold — so VaR is always included inside the CVaR tail, not one observation outside it.
Anton Ladnyi, CFA · A.L. Capital AdvisoryUpdated 2026-08-08
Rating Rationale
MRK — Q2 2026 (reported Aug 4) beat on both lines: revenue $16.61B (+5% YoY, beat $16.36B est.) with Keytruda up 5% to $8.37B (including $463M from the new subcutaneous QLEX formulation, itself beating estimates); but GAAP EPS was a loss of $0.13 including a $2.31/share charge tied to the newly-closed $6.7B Terns Pharmaceuticals acquisition, and full-year adjusted EPS guidance was cut sharply to $2.66-2.76 (from $5.04-5.16) purely on Terns/Cidara deal charges even as full-year revenue guidance was nudged up to $66.3-67.3B.
Investment Thesis
↑ Bull Case
Keytruda beat estimates ($8.37B vs. $8.27B consensus) with QLEX (subcutaneous formulation) contributing $463M and showing stronger-than-expected uptake per management commentary — the franchise is still growing into 2028's patent cliff, not decelerating ahead of it
Non-Keytruda growth drivers are scaling fast: Winrevair $588M (+75% YoY, beat $565M est.), Welireg $271M (+67% YoY), Capvaxive $184M (+42% YoY) — a genuine multi-product diversification base is forming ahead of the patent cliff, not just pipeline promises
Full-year revenue guidance was raised (not cut) to $66.3-67.3B despite the EPS guidance cut being entirely attributable to one-time M&A charges from closing the Terns and Cidara acquisitions — the underlying operating business outperformed
Pipeline execution continued: FDA approval of LIPFENDRA (first oral PCSK9 inhibitor), positive Phase III data in endometrial cancer (sac-TMT) and ulcerative colitis (tulisokibart), and Phase III success for the once-weekly islatravir/lenacapavir HIV regimen — the post-Keytruda pipeline breadth keeps expanding
The Terns acquisition adds MK-4208 for CML, directly extending the oncology pipeline beyond Keytruda-dependent revenue, consistent with management's stated strategy of buying growth ahead of the 2028 cliff
↓ Bear Case
The EPS guidance cut is severe in magnitude (roughly halved, from $5.04-5.16 to $2.66-2.76) — even if entirely attributable to M&A charges, it materially changes the near-term earnings optics and could pressure the stock on headline EPS misses through the charge-absorption period
The GAAP loss per share this quarter, even with a clear one-time explanation, adds to a pattern of Merck using large, dilutive-to-current-earnings acquisitions (Terns $6.7B, plus Cidara) to build the post-2028 pipeline — the cumulative drag on near-term reported earnings could weigh on sentiment even as revenue guidance improves
Keytruda remains ~50% of total revenue; even with the QLEX subcutaneous formulation extending its commercial life, the 2028 patent cliff is now two years closer and the diversification products (Winrevair, Welireg, Capvaxive) are still a fraction of Keytruda's scale
Integration risk on two recent acquisitions (Terns, Cidara) closing in quick succession adds execution complexity at exactly the time management needs pipeline conversion to go smoothly to offset the Keytruda cliff
What Changes the Rating
↑Catalyst:Q3 adjusted EPS shows the charge-related drag was genuinely one-time with a clear path back toward the pre-cut $5+ run-rate; Keytruda + Padcev MIBC PDUFA decision is a positive approval; Winrevair/Welireg/Capvaxive growth rates hold or accelerate
↓Model downgrade conditions:Adjusted EPS guidance is cut again on operational (not one-time M&A) grounds; Keytruda growth decelerates below 3% YoY; the Aug 17 Padcev/MIBC PDUFA decision is a rejection or delay
Anton’s personal note
The model points to a strong buy and the DCF math backs it — there is real margin of safety here, which is rare at this stage of the cycle. The variable I track most closely is gross margin trajectory. That multiple can only be sustained if operating leverage is real — specifically whether the margin profile at scale supports what the market is already pricing in, or whether that future still needs to be earned. The setup that would make me more positive is a quarter that confirms the operating leverage story. The setup that would make me cautious is any signal that consensus estimates are getting ahead of fundamentals.
— Anton Ladnyi, CFA
Earnings History
MRK Earnings History — EPS Surprise Rate 2026
Quarter
EPS Est. (consensus)
EPS Actual (adjusted, consensus basis)
Surprise
Q2 2026
$-0.26
$-0.13
+49.4% ✓
Q1 2026
$-1.47
$-1.28
+13.2% ✓
Q4 2025
$2.01
$2.04
+1.5% ✓
Q3 2025
$2.35
$2.58
+9.8% ✓
EPS Actual is on the same adjusted/non-GAAP basis as the consensus estimate it is compared against (excludes one-time items, consistent with how Wall Street EPS estimates are typically constructed) — it will generally differ from the company's GAAP diluted EPS as reported in its official financial statements. Verify the GAAP figure against the issuer's original earnings release if that basis is what you need.
How Has MRK Performed vs. Wall Street EPS Estimates?
MRK has beaten consensus EPS estimates in 4 of the last 4 reported quarters (100%).
MRK quarterly EPS — estimate vs. actual, 4 most recent reported quarters, 100% beat rate.
Earnings Projections
MRK Forward EPS Consensus Estimates 2026
Quarter
EPS Est.
YoY EPS
Analysts
Q3 2026
$2.22
-14.0%
16
Q4 2026
$1.96
-4.0%
16
Q1 2027
~$2.40
+287.5%
23
Q2 2027
~$2.40
+1946.2%
23
~ Estimated from annual consensus — not a direct analyst survey
What Are Wall Street's EPS Estimates for MRK?
Wall Street's next-quarter consensus EPS estimate for MRK is $2.22.
MRK consensus EPS estimates, next quarter $2.22, 4 quarters shown.
Revenue growth × exit multiple (editorial, not mechanically reproducible from disclosed inputs) · hover each scenario for detail · current price $128.58
▼
Bear Case
$68
-47.1%
Implied NTM P/E: 7.6x (target ÷ next-4Q consensus EPS — distinct from the exit multiple below, which is applied to a later-year EPS estimate)
0% revenue CAGR · 12x exit multiple
◆
Base Case
$92
-28.4%
Implied NTM P/E: 10.2x (target ÷ next-4Q consensus EPS — distinct from the exit multiple below, which is applied to a later-year EPS estimate)
4% revenue CAGR · 15x exit multiple
▲
Bull Case
$118
-8.2%
Implied NTM P/E: 13.1x (target ÷ next-4Q consensus EPS — distinct from the exit multiple below, which is applied to a later-year EPS estimate)
8% revenue CAGR · 18x exit multiple
How Correlated Is MRK With Its Sector Peers?
0 of 6 peer pairs correlated above 0.60, indicating meaningful historical diversification across the selected names, although all remain exposed to common equity, sector and macro factors.
MRK pairwise correlation heatmap across 4 peers — 0 of 6 pairs above 0.60.
0 of 6 peer pairs correlated above 0.60, indicating meaningful historical diversification across the selected names, although all remain exposed to common equity, sector and macro factors.
Extended Analysis — Buy, Hold or Sell? Risk Factors. Portfolio Fit.
Is MRK a buy, hold, or sell?
MRK carries a quantitative grade of Strong Buy. The trailing P/E of 102.9 sits 368% above the Healthcare sector median of 22.0x — a premium that demands sustained earnings delivery. Our two-stage, EPS-based DCF model produces a pure model range of $195–$390. After blending with Street consensus targets, the displayed fair-value range is $128–$214 — implying a +25% margin of safety vs. blended base fair value at the current price of $128.58. The width of the range reflects genuine uncertainty in the terminal growth rate assumption: the correct framework is a probability-weighted distribution over scenarios, not a single point estimate. See the DCF valuation framework for full methodology.
MRK has beaten consensus estimates in 100% of the last 4 reported quarters, signalling strong execution consistency. The most recent quarter delivered a 49.4% earnings surprise. Analyst estimate revisions are trending upward.
What are MRK's key risk factors?
With a beta of 0.21, MRK exhibits a low-volatility risk profile relative to the broad market. The 95th-percentile CVaR of -8.3% on a one-month horizon should inform position sizing directly: at a 10% portfolio weight, this standalone tail outcome corresponds to approximately 0.8% of portfolio value before accounting for correlations with other holdings — not a marginal portfolio CVaR contribution, which depends on the full covariance structure. Net margins of 4.8% fall below the Healthcare sector average of 18%, suggesting margin pressure. Leverage is moderate with debt-to-equity at 107%.
At 0.40, the put/call ratio skews bullish, with call buyers dominating recent flow. Implied volatility of 29.0% exceeds realized volatility of 23.7% by 5 points, suggesting options are pricing in elevated risk. Insider transactions show net buying of $25.9M over the disclosed transactions from 2025-01-27 to 2026-05-01, a signal often associated with management confidence. Short interest is low at 1.2% of float, suggesting limited bearish conviction.
How does MRK fit in a diversified portfolio?
At typical HENRY portfolio weights — 10–20% of the equity allocation — MRK carries a beta of 0.21, meaning it amplifies broad market moves proportionally. The appropriate weight is not a function of conviction alone, but of the full covariance structure across all holdings. See the Ledoit-Wolf covariance framework for the methodology behind these calculations.
Among closely correlated names, MRK shows the strongest co-movement with PFE (0.52), JNJ (0.50), LLY (0.42). Investors seeking diversification should note these correlation dynamics when constructing multi-asset portfolios.
True portfolio risk is a function of the full covariance structure across all holdings — not individual stock metrics. The Portfolio Health Check quantifies this at the portfolio level: it surfaces hidden concentration, marginal CVaR contributions, and the degree to which your overall allocation deviates from an optimal risk-adjusted mandate. The MRK analysis here is a single node in that larger structure.
For the portfolio construction framework underpinning MRK’s position sizing and conviction rating — including IPS guardrails, Black-Litterman allocation, and CVaR constraints — see: Investment Policy Statement Framework →
Investor FAQ
What is MRK's AI-Era Durability & Disruption Risk Score?
Merck's durability picture is a single-product concentration story: Keytruda generated $29.5 billion in 2024 revenue, roughly 40% of pharmaceutical sales, and loses U.S. exclusivity in late 2028 in what the industry frames as the largest single revenue-replacement challenge in modern pharma. Merck's defense combines lifecycle management -- the Keytruda QLEX subcutaneous reformulation targeting 30-40% patient conversion by 2028 to blunt biosimilar erosion -- with acquisitions (Prometheus for $10.8 billion in 2023, plus Verona Pharma and Cidara Therapeutics) meant to diversify into cardio-respiratory, immunology, and infectious-disease franchises; management now projects over $70 billion in non-risk-adjusted pipeline commercial opportunity by the mid-2030s. Near term, Gardasil sales fell 39% to about $5.2 billion in 2025 on China demand weakness and inventory overhang, an added drag layered on top of the looming Keytruda cliff. AI is not a meaningful driver of Merck's 2026 investment case. Watch trigger: adoption of Keytruda QLEX and whether Winrevair, Ohtuvayre, and tulisokibart show franchise-level revenue traction ahead of 2028.
What is MRK's intrinsic value and DCF price target?
A.L. Capital Advisory's model produces a blended fair-value range (25% pure DCF, 75% analyst consensus for well-covered names) of $128 (bear case) to $214 (bull case) for Merck & Co. Inc. (MRK). At $128.58, the margin of safety vs. blended base case is +25% (positive = discount to fair value; negative = premium). The bear-to-bull spread reflects genuine sensitivity to the two dominant DCF inputs: the terminal growth rate and the CAPM cost of equity (this model discounts EPS, an equity-level metric, so the cost of equity rather than a debt-weighted WACC is the applicable discount rate). Terminal value typically accounts for 60-80% of total intrinsic value in most equity DCF models, which is why a range is more analytically sound than a point estimate. The central analytical question is not what the DCF outputs as a single number but which growth trajectory the current market price already discounts. All DCF analysis follows CFA Institute standards and is conducted by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: DCF Valuation Framework →
Is MRK a buy or sell in 2026?
Merck & Co. Inc. (MRK) carries a Strong Buy quantitative rating from A.L. Capital Advisory, set by Discounted Cash Flow margin-of-safety band with no analyst-conviction overlay applied. Five-factor model scoring (Value, Quality, Momentum, Volatility, Size) and CVaR tail risk measurement are shown separately on the page. At $128.58, the margin of safety vs. blended base fair value is +25% (blended fair-value range: $128 bear – $214 bull). That places the current price in the Fair Range zone of A.L. Capital Advisory's DCF framework, which sets the quantitative grade component that determines this rating. Composite factor score: 3.5/5. Strongest factor: Volatility (5.0/5). Weakest factor: Value (2.0/5). Trailing P/E: 102.9x. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: Rating Methodology (this page) →
What is the average analyst target price for MRK?
Wall Street consensus target for MRK: $136.65 (+6.3% upside from the current price of $128.58). The analyst target range spans $105.00 (most bearish) to $155.00 (most bullish). Consensus recommendation: Buy. Note that analyst price targets typically reflect a 12-month forward horizon and are derived from a blend of DCF, comparable-company, and sum-of-the-parts analysis. A.L. Capital Advisory's Strong Buy composite rating is calculated from the blended margin-of-safety grade, applicable automatic fundamental penalties, and a disclosed qualitative analyst-conviction overlay — not from five-factor scores or CVaR, which are supporting diagnostics shown elsewhere on this page. The displayed blended fair value combines the standalone DCF output with Street consensus for well-covered names (see the DCF Assumptions box for the exact blend weight), so it does not track Street consensus mechanically, but it is not fully independent of it either. When the composite rating and the Street consensus recommendation diverge, the divergence itself is informative: it can reflect differences in time horizon, valuation methodology, or the degree to which the current price already discounts the consensus case. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: Data & Sources (this page) →
How does MRK score on Value, Quality, Momentum, Volatility, and Size?
MRK five-factor scores (A.L. Capital Advisory, 1–5 scale): Value 2.0/5 (below average) — measures the trailing P/E multiple versus the sector median (not the DCF or blended fair-value range, which are separate metrics on this page); Quality 3.0/5 (neutral) — captures profitability metrics including return on equity and net margin (4.8%) — sustained above-peer ROE and margins are the model's proxy for economic moat and pricing power; Momentum 3.0/5 (neutral) — reflects recent price trajectory and earnings surprise consistency; Volatility 5.0/5 (strong) — inverse measure derived from beta, where lower historical volatility earns a higher score; Size 4.5/5 (strong) — market capitalisation rank (mega-cap $1T+ scores 5/5). Composite: 3.5/5. Factor scores above 4.0 signal a tailwind in that dimension; below 2.0 signals a material headwind. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory.
What is MRK's tail risk and CVaR?
The 95th-percentile Conditional Value at Risk (CVaR) for MRK on a one-month horizon is -8.3%. CVaR represents the expected average loss in the worst 5% of monthly outcomes — a more conservative tail risk measure than standard VaR, which only marks the loss threshold. Beta of 0.21 indicates below-market systematic sensitivity — beta measures historical sensitivity to market moves, not total volatility. For reference, a diversified S&P 500 ETF carries a one-month CVaR of roughly -8% to -12% in normal market conditions; individual equity CVaR is higher due to idiosyncratic risk. At the portfolio level, what matters is the marginal CVaR contribution of each holding — not its standalone figure. The A.L. Capital Advisory Portfolio Health Check quantifies each position's marginal tail-risk contribution across your entire holdings. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: CVaR & Tail-Risk Methodology →
What would trigger a rating upgrade or downgrade for MRK?
Higher-conviction trigger: Evidence supporting the upper end of the Strong Buy range, such as accelerating earnings surprise magnitude combined with improvement in the Value factor score — specifically if the current 102.9x P/E is supported by an upward revision to DCF terminal growth assumptions. Downgrade trigger: An earnings miss at current valuations (102.9x trailing P/E) where there is limited earnings cushion to absorb negative surprises; or a sustained reversal in the Quality and Momentum factor scores for two or more consecutive quarters. These triggers are reassessed each time the underlying fundamentals, price, or earnings data refresh — the current Strong Buy rating is not held on a fixed review calendar. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: Rating Methodology (this page) →
Does MRK consistently beat earnings estimates?
MRK has beaten consensus EPS estimates in 4 of the 4 most recently reported quarters (100%) — indicating consistent delivery across the latest 4 reported quarters. The most recent reported quarter beat consensus by 49.4%. Sustained above-consensus delivery supports both the Momentum and Quality factor scores and provides a tailwind to the current rating. Across the 4 most recently reported quarters with valid consensus data, a beat rate above 70% signals consistent execution in this model, while a rate below 50% typically corresponds to a Momentum factor score of 3.0/5 or below. Earnings surprise magnitude and direction are incorporated into the Momentum and Quality dimensions of the five-factor scoring model. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: Earnings History (this page) →
How does MRK contribute to portfolio risk and diversification?
MRK carries a beta of 0.21 (low-volatility / defensive relative to the broad equity market). A beta above 1.0 means the position amplifies market moves in both directions at a typical portfolio weight. Strongest peer co-movement: PFE (0.52), JNJ (0.50), LLY (0.42). Holding MRK alongside these names in the same portfolio increases concentration risk. True portfolio risk is a function of the full covariance structure — a single stock's beta does not reveal its marginal contribution to portfolio tail loss. The A.L. Capital Advisory Portfolio Health Check quantifies concentration risk (Herfindahl-Hirschman Index), pairwise correlations, and marginal CVaR contribution across all your holdings. If a single position such as this one makes up an outsized share of your net worth — employer stock, RSUs, or concentrated equity compensation — a Strategic Session builds the sequencing plan and the written allocation that follows from it. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: Ledoit-Wolf Covariance Framework →
What quantitative methodology does A.L. Capital Advisory use to analyse MRK?
A.L. Capital Advisory analyses Merck & Co. Inc. (MRK) using a four-part quantitative research framework grounded in CFA Institute standards (not all four parts feed the composite rating formula directly — see below). (1) DCF Valuation: a two-stage earnings-based DCF that projects EPS (not free cash flow) under bear and bull assumptions, discounts at the CAPM cost of equity (the applicable rate for an equity-level metric like EPS, not a debt-weighted WACC) to produce an intrinsic value range with margin-of-safety calculation. (2) Five-Factor Scoring: each equity is scored 1–5 on Value, Quality, Momentum, Volatility, and Size. (3) CVaR Tail Risk: 95th-percentile Conditional Value at Risk from historical simulation of daily returns on a one-month horizon. (4) Earnings Surprise Analysis: quarterly beat rate and magnitude, shown for context alongside the factor scores. The current Strong Buy composite rating for MRK is calculated separately from this broader framework: it consists of a Strong Buy quantitative grade, any automatic fundamental penalty, and a disclosed qualitative analyst-conviction overlay — see this page's Rating Methodology section for the exact formula. Five-factor scoring, CVaR and earnings surprise analysis below are supporting research diagnostics shown separately on this page; they are not direct numerical inputs into this specific composite-rating calculation. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: DCF Valuation Framework → · CVaR & Tail-Risk Methodology →
Stress-Test This View Live
Run MRK in Asset Lens
Live DCF valuation, Monte Carlo simulation, options flow intelligence, and full factor decomposition — updated in real time. Free, no account required.
Retrieved 2026-08-08T12:43:46+00:00 (UTC); see per-quarter analyst counts in Earnings Forecast; individual target ages/dates are not disclosed by the data provider
Most recent exchange settlement date on file with the data provider (exact settlement date not exposed by the provider's API; retrieved 2026-08-08T12:43:46+00:00 UTC)
[6] DCF valuation, five-factor model & composite rating
Calculated 2026-08-08T12:43:46+00:00 (UTC); see Rating Methodology above for the exact formula
Hand-authored thesis commentary (bull/bear case, catalysts, AI-Era Durability Score narrative) is cross-checked against the company's own investor-relations disclosures at time of writing; figures presented as A.L. Capital Advisory estimates are proprietary forecasts, not company guidance, unless explicitly attributed to the issuer.
Market-session status above is derived from the page's UTC generation time using standard NYSE hours (9:30am–4:00pm ET regular session); it does not account for US market holidays and may be inaccurate on those dates.
Download this page's underlying data: JSON → · CSV →
Legal Disclaimer & Important Notices
This analysis is produced using a systematic quantitative framework applied to market data and does not constitute investment advice. Prose commentary is AI-assisted and generated from structured quantitative inputs. All data and metrics are as of 2026-08-08 and are point-in-time estimates subject to revision without notice. CVaR figures are based on historical simulation and do not guarantee future outcomes. DCF ranges and upgrade/downgrade triggers are forward-looking statements based on current assumptions and may not materialise. Past performance does not guarantee future results. This analysis does not account for individual circumstances, tax position, or investment objectives — consult a qualified financial advisor before making investment decisions. This content is intended for informational purposes only and does not constitute regulated investment advice under MiFID II or FCA guidelines. This content is not intended for US persons or residents of jurisdictions where its distribution would be contrary to local law or regulation. This service is not directed at residents of Finland, Sweden, Norway, Denmark, Iceland, or Poland. The author may hold long or short positions in securities mentioned in this analysis. Nothing on this page represents a solicitation to buy or sell any security. A.L. Capital Advisory is an independent private advisory practice and is not affiliated with Merck & Co. Inc.
CFA Portfolio Advisory — MRK
Discuss this analysis, position sizing, or your full portfolio mandate with Anton Ladnyi, CFA.
